Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL88358 | 0.94 | MEN1 (0.39) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL138365 | 0.94 | MEN1 (0.46) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL7780196 | 0.88 | — | — | |
| Sulfuric Acid SCHEMBL1181094 | 0.88 | — | — | |
| Sulfuric Acid SCHEMBL17289024 | 0.88 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL3064645 | 0.88 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL3267573 | 0.88 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL11045817 | 0.88 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL54795 | 0.88 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL8865673 | 0.88 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080199420-A1 | Cosmetic oil in water emulsion ofamphiphilic polymer with hydrophilic and hydrophobic units formed from polyisobutenes modified with terminal polar groups, emulsifier, oil and water; ethylene oxide-propylene oxide block polymer modified polyisobutenyl succinic anhydride; hydroxylation, epoxidation | BASF AKTIENGESELLSCHAFT (DE) | 2008-08-21 | — | — | US | disclosed |
| US-6559344-B2 | Hydroformylation | BASF AKTIENGESELLSCHAFT (DE) | 2003-05-06 | — | — | US | disclosed |
| US-20020115892-A1 | Of ethylenically unsaturated compounds using at least one complex or compound of a metal of transition group VIII with at least one bidentate phosphine ligand as hydroformylation catalyst | BASF AKTIENGESELLSCHAFT (DE) | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115892-A1 | Of ethylenically unsaturated compounds using at least one complex or compound of a metal of transition group VIII with at least one bidentate phosphine ligand as hydroformylation catalyst | ETFB, ETFA, ELOVL6 | MEN1 1712/4885ALDH1A1 1491/4885TSHR 4444/4885 |
| US-20080199420-A1 | Cosmetic oil in water emulsion ofamphiphilic polymer with hydrophilic and hydrophobic units formed from polyisobutenes modified with terminal polar groups, emulsifier, oil and water; ethylene oxide-propylene oxide block polymer modified polyisobutenyl succinic anhydride; hydroxylation, epoxidation | HAO2, LRBA, POLB | MEN1 4660/4885ALDH1A1 1290/4885TSHR 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.